Isansys Lifecare, a digital healthcare company which has developed the world’s most advanced real-time patient data collection and analysis platform for early detection of deterioration in patients, has been granted a US patent covering a key feature of its Lifetouch cardiac sensor. The US patent adds to a suite of already issued European patents for the wireless smart patch device.
Ample warning of negative effects enables clinicians to intervene more quickly and confidently and thereby improve patient outcomes.
The Lifetouch is a vital component of the Patient Status Engine (PSE), a Class 11 (CE and FDA) continuous multiple vital sign patient monitoring platform that automatically and continuously collects and analyzes patients’ vital signs to provide real-time information and predictive insights for clinicians, nurses and for patients themselves. This data is then streamed via a proprietary patient gateway network and delivered to the nurses’ station or remotely to clinicians, reports Isansys.
“The granting of this patent in the US for the Lifetouch is an important step in reconfiguring the idea of a medical device from product to AI augmented platform. The patented technology enhances the Patient Status Engine creating an even smarter platform that can dynamically reprogram the Lifetouch according to what it is detecting in an individual. This means healthcare providers receive more specific, higher resolution data leading to faster diagnostics and better care for the patient,” said Keith Errey, CEO of Isansys.
Worldwide, clinical teams are already utilizing the data collected and analyzed by the PSE to gain insights into the future health status of their patients. The system enables doctors and nurses to enhance patient outcomes and lower the costs of dealing with patient safety issues and shorten hospital stays. As the system is wireless, it allows patients to be monitored in hospitals, in the community or at home.